HTSUY (Hisamitsu Pharmaceutical Co) Cyclically Adjusted Revenue per Share: $3.21 (As of Nov. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HTSUY Hisamitsu Pharmaceutical Co Inc HTSUY
67 GF Score
Price $2.94
GF Value $7.43
Valuation Significantly Undervalued
View Full Analysis

What is Hisamitsu Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Hisamitsu Pharmaceutical Co HTSUY 67 Cyclically Adjusted Revenue per Share is $3.21 as of Nov. 2025. GuruFocus rates HTSUY with a GF Score™ of 67/100 and a GF Value™ of $7.43 (Significantly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Hisamitsu Pharmaceutical Co's adjusted revenue per share for the three months ended in Nov. 2025 was $0.888. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.21 for the trailing ten years ended in Nov. 2025.

During the past 12 months, Hisamitsu Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Hisamitsu Pharmaceutical Co was 2.70% per year. The lowest was -0.30% per year. And the median was -0.10% per year.

As of today (2026-07-28), Hisamitsu Pharmaceutical Co's current stock price is $2.94. Hisamitsu Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Nov. 2025 was $3.21. Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 0.92.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hisamitsu Pharmaceutical Co was 4.97. The lowest was 2.06. And the median was 2.88.


Hisamitsu Pharmaceutical Co  (OTCPK:HTSUY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.94/3.21
=0.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hisamitsu Pharmaceutical Co was 4.97. The lowest was 2.06. And the median was 2.88.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Hisamitsu Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Hisamitsu Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.53 2.67 3.34 3.02 0.00

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.02 3.04 3.25 3.21 0.00

HTSUY vs AMPH, ESPR, NIKA: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hisamitsu Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


HTSUY
67GF Score
Hisamitsu Pharmaceutical Co Inc HTSUY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hisamitsu Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Nov. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Nov. 2025 (Change)*Current CPI (Nov. 2025)
=0.888/113.2000*113.2000
=0.888

Current CPI (Nov. 2025) = 113.2000.

Hisamitsu Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201602 1.019 97.800 1.179
201605 1.035 98.200 1.193
201608 1.054 97.900 1.219
201611 0.959 98.600 1.101
201702 0.957 98.100 1.104
201705 0.960 98.600 1.102
201708 1.016 98.500 1.168
201711 0.955 99.100 1.091
201802 1.076 99.500 1.224
201805 0.912 99.300 1.040
201808 0.965 99.800 1.095
201811 0.875 100.000 0.991
201902 1.113 99.700 1.264
201905 0.804 100.000 0.910
201908 0.973 100.000 1.101
201911 1.002 100.500 1.129
202002 1.165 100.300 1.315
202005 0.711 100.100 0.804
202008 0.808 100.100 0.914
202011 0.817 99.500 0.929
202102 0.977 99.800 1.108
202105 0.778 99.400 0.886
202108 0.856 99.700 0.972
202111 0.756 100.100 0.855
202202 0.910 100.700 1.023
202205 0.642 101.800 0.714
202208 0.769 102.700 0.848
202211 0.710 103.900 0.774
202302 0.875 104.000 0.952
202305 0.753 105.100 0.811
202308 0.775 105.900 0.828
202311 0.781 106.900 0.827
202402 0.857 106.900 0.908
202405 0.766 108.100 0.802
202408 0.923 109.100 0.958
202411 0.787 110.000 0.810
202502 1.003 110.800 1.025
202505 0.819 111.800 0.829
202508 0.942 112.100 0.951
202511 0.888 113.200 0.888

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $3.21 mean?
Hisamitsu Pharmaceutical Co (HTSUY) has a Cyclically Adjusted Revenue per Share of $3.21 as of Nov. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Hisamitsu Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $3.21. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to AMPH and ESPR?
Hisamitsu Pharmaceutical Co's Cyclically Adjusted Revenue per Share of $3.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co (HTSUY) is currently considered Significantly Undervalued. The stock's GF Value™ is $7.43, compared to a current price of $2.94 — trading 60.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $3.21. Hisamitsu Pharmaceutical Co's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (HTSUY), the current Cyclically Adjusted Revenue per Share is $3.21 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (HTSUY) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be undervalued. The current stock price of $2.94 is trading 60.4% below its estimated GF Value™ of $7.43. GuruFocus considers Hisamitsu Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for HTSUY:

  • Cyclically Adjusted Revenue per Share: $3.21
  • GF Value™: $7.43 vs. price of $2.94 (60.4% below fair value)
  • GF Score™: 67/100

No single metric tells the full story. See the HTSUY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hisamitsu Pharmaceutical Co Business Description

Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
67GF Score

Get the complete analysis for HTSUY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.94
Price
$7.43
GF Value